Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

首次发布于 2025 年 12 月 4 日

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

计划入组 16 人 · 首次发布于 2025 年 3 月 18 日

Is the Normal Looking Bladder Mucosa on WL Cystoscopy During TURBT Really Normal and Can NBI Detect Hidden Tumor

计划入组 100 人 · 首次发布于 2024 年 12 月 11 日

HI-1640V

HI-321

HI-280

Stiftung Swiss Tumor Institute

Switzerland

HI TECH PHARMACAL CO INC

United States

HI-TECH PHARMACAL CO., INC.

United States

Ersodetug Receives FDA Orphan Drug Designation for Tumor-Induced Hypoglycemia

Rezolute's Ersodetug Advances in Phase 3 Trials for Hyperinsulinism

FDA Approves Vorasidenib (Voranigo) for IDH-Mutant Glioma, Developed from Duke Neurosurgeon's Discovery